-
Publication Venue For
-
What can heart failure trialists learn from oncology trialists?.
42:2373-2383.
2021
-
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score..
42:1676-1684.
2021
-
The association between coronary graft patency and clinical status in patients with coronary artery disease..
42:1433-1441.
2021
-
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction..
42:919-933.
2021
-
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC..
42:373-498.
2021
-
Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy..
41:4505-4507.
2020
-
Predicting outcome in cardiac arrest: some progress, but more work needed..
41:4518-4520.
2020
-
Managing patients with ST-elevation myocardial infarction and multivessel disease: is the story complete?.
41:4111-4113.
2020
-
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation..
41:4037-4046.
2020
-
Towards a better standard for defining high bleeding risk patients: can we now translate this into a better practice?.
41:3750-3752.
2020
-
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS..
41:3533-3545.
2020
-
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial..
41:3451-3458.
2020
-
Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes..
41:3132-3140.
2020
-
Prevention of cardiovascular disease: time for a course correction..
41:3016-3017.
2020
-
Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis..
41:2248-2258.
2020
-
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)..
41:2109-2117.
2020
-
Novel approaches to the management of chronic systolic heart failure: future directions and unanswered questions..
41:1764-1774.
2020
-
Call me maybe? The right time and place for BPAs in EHRs..
41:1097-1099.
2020
-
Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group..
41:1132-1140.
2020
-
Impact of renin-angiotensin system inhibitors on clinical outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis of from the PARTNER 2 trial and registries..
41:943-954.
2020
-
Antithrombotic therapy after acute coronary syndrome and/or percutaneous coronary intervention in atrial fibrillation: finding the sweet spot..
40:3768-3770.
2019
-
Must I keep taking all these medicines? Optimizing diuretics in chronic heart failure..
40:3613-3615.
2019
-
Cardiovascular biomarkers in patients with acute decompensated heart failure randomized to sacubitril-valsartan or enalapril in the PIONEER-HF trial..
40:3345-3352.
2019
-
Continuous anticoagulation with catheter ablation: answers and questions..
40:3022-3025.
2019
-
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial..
40:2801-2809.
2019
-
Management of cardiogenic shock complicating myocardial infarction: an update 2019..
40:2671-2683.
2019
-
Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk..
40:2632-2653.
2019
-
The optimal antithrombotic regimen to prevent post-CABG adverse events: an ongoing controversy..
40:2441-2443.
2019
-
The continuous heart failure spectrum: moving beyond an ejection fraction classification..
40:2155-2163.
2019
-
Application of net reclassification index to non-nested and point-based risk prediction models: a review..
40:1880-1887.
2019
-
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials..
40:1492-1500.
2019
-
Reply to letter by Bamford et al. regarding the article: Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial..
40:1568.
2019
-
Atrial fibrillation ablation in practice: assessing CABANA generalizability..
40:1257-1264.
2019
-
Risk stratification for stroke in atrial fibrillation: a critique..
40:1294-1302.
2019
-
Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial..
40:743-751.
2019
-
Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies..
40:621-631.
2019
-
Fourth universal definition of myocardial infarction (2018)..
40:237-269.
2019
-
Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF..
39:4255-4256.
2018
-
Modes and timing of death in 66 252 patients with non-ST-segment elevation acute coronary syndromes enrolled in 14 TIMI trials..
39:3810-3820.
2018
-
Real-world clinical utility and impact on clinical decision-making of coronary computed tomography angiography-derived fractional flow reserve: lessons from the ADVANCE Registry..
39:3701-3711.
2018
-
An update on the journey towards precision medicine in cardiology..
39:3627-3628.
2018
-
The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial..
39:3464-3471.
2018
-
Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation..
39:2942-2955.
2018
-
Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe..
39:2932-2941.
2018
-
Uninterrupted apixaban for atrial fibrillation ablation is a reasonable alternative, but what is the significance of silent cerebral infarctions?.
39:2956-2958.
2018
-
The incidence and prognostic implications of worsening right ventricular function after surgical or transcatheter aortic valve replacement: insights from PARTNER IIA..
39:2659-2667.
2018
-
Japan-United States of America Harmonized Assessment by Randomized Multicentre Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE) study: primary results of the pivotal registration study of combined endothelial progenitor cell capture and drug-eluting stent in patients with ischaemic coronary disease and non-ST-elevation acute coronary syndrome..
39:2460-2468.
2018
-
Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke..
39:2376-2386.
2018
-
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials..
39:2208-2216.
2018
-
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document..
39:2192-2207.
2018
-
Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative..
39:1687-1697.
2018
-
Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation..
39:1706-1708.
2018
-
Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?.
39:1438-1441.
2018
-
Cardiomyopathy in Friedreich's Ataxia..
39:631.
2018
-
A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score..
39:477-485.
2018
-
Improving outcomes after catheter ablation of atrial fibrillation: better patient selection, better procedure, or both?.
39:450-452.
2018
-
Oral anticoagulation: a step toward solving the puzzle of dementia related to atrial fibrillation?.
39:461-463.
2018
-
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy..
39:193-200.
2018
-
Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials..
38:3502-3510.
2017
-
Staging classification of aortic stenosis based on the extent of cardiac damage..
38:3351-3358.
2017
-
Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke..
38:2827-2835.
2017
-
Global position paper on cardiovascular regenerative medicine..
38:2532-2546.
2017
-
Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough?.
38:2440-2443.
2017
-
Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)..
38:2364-2373.
2017
-
Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary..
38:2137-2149.
2017
-
Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges..
38:1805-1814.
2017
-
Succinate dehydrogenase gene mutation with cardiac paraganglioma: multimodality imaging and pathological correlation..
38:1853-1854.
2017
-
HIV infection, ACS, PCI and high platelet reactivity: ingredients for a perfect thrombotic storm..
38:1687-1689.
2017
-
Infarct size, left ventricular function, and prognosis in women compared to men after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: results from an individual patient-level pooled analysis of 10 randomized trials..
38:1656-1663.
2017
-
Left atrial appendage occlusion: rationale, evidence, devices, and patient selection..
38:869-876.
2017
-
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial..
38:804-810.
2017
-
Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial..
38:648-660.
2017
-
A review of sex-specific benefits and risks of antithrombotic therapy in acute coronary syndrome..
38:165-171.
2017
-
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial..
37:3576-3584.
2016
-
A view from the side-line..
37:3488-3489.
2016
-
Anticoagulation in coronary intervention..
37:3376-3385.
2016
-
Genetic cardiovascular risk prediction: are we already there?.
37:3279-3281.
2016
-
Risk stratification in non-ST elevation acute coronary syndromes: searching for the right formula..
37:3111-3113.
2016
-
The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial..
37:2869-2878.
2016
-
Aortic valve surgery and survival in patients with moderate or severe aortic stenosis and left ventricular dysfunction..
37:2276-2286.
2016
-
Outcomes of transfemoral transcatheter aortic valve implantation at hospitals with and without on-site cardiac surgery department: insights from the prospective German aortic valve replacement quality assurance registry (AQUA) in 17 919 patients..
37:2240-2248.
2016
-
Finerenone in heart failure: walking a fine line..
37:2115-2117.
2016
-
Left atrial appendage to great cardiac vein fistula complicating watchman left atrial appendage closure..
37:1602.
2016
-
The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation..
37:1582-1590.
2016
-
Genetic variants and disease: correlate or cause?.
37:1476-1478.
2016
-
Assessing generalizability of trial results in general practice..
37:1154-1157.
2016
-
Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma..
37:1143-1144.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.
2016
-
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2.
2016
-
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome..
37:412-422.
2016
-
CardioPulse: Platelet inhibitors and their differences..
37:323-326.
2016
-
Lessons learned and a look to the future: the Chronic Ischemic Heart Disease (CICD) Pilot Registry..
37:161-163.
2016
-
Nox4 NADPH oxidase: emerging from the veil of darkness..
36:3457-3459.
2015
-
Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFR(CT): outcome and resource impacts study..
36:3359-3367.
2015
-
Atrial fibrillation in heart failure: what should we do?.
36:3250-3257.
2015
-
Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial..
36:3268-3275.
2015
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.
36:3258-3264.
2015
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation..
36:3258-3264.
2015
-
Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction..
36:2733-2741.
2015
-
Augmenting outcomes in patients with advanced heart failure..
36:2276-2278.
2015
-
Reversal of right-ventricular dysfunction in pulmonary arterial hypertension following sildenafil therapy..
36:2018.
2015
-
Cardiovascular precision medicine: hope or hype?.
36:1842-1843.
2015
-
Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium..
36:1851-1877.
2015
-
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes..
36:1901-1912.
2015
-
Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention..
36:1762-1771.
2015
-
Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)..
36:1689-1696.
2015
-
The detection and treatment of subclinical atrial fibrillation: evaluating the IMPACT of a comprehensive strategy based on remote arrhythmia monitoring..
36:1640-1642.
2015
-
Should patients on vitamin K antagonists be treated differently?.
36:1431-1433.
2015
-
Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial..
36:1264-1272.
2015
-
Management of cardiogenic shock..
36:1223-1230.
2015
-
The end of an electrocardiographic dogma: a prominent R wave in V1 is caused by a lateral not posterior myocardial infarction-new evidence based on contrast-enhanced cardiac magnetic resonance-electrocardiogram correlations..
36:959-964.
2015
-
Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers..
36:847-855.
2015
-
Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program..
36:669-675.
2015
-
Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension..
36:566-575.
2015
-
LCZ696: too good to be true?.
36:410-412.
2015
-
Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial: characterizing patients and impact on outcomes..
36:449-456.
2015
-
The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling..
36:440-448.
2015
-
Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial..
36:385-92a.
2015
-
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial..
36:288-296.
2015
-
Paradoxical embolism in Ebstein's anomaly..
36:315.
2015
-
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial..
36:219-227.
2015
-
Chest pain in patients with heart failure: why history may matter..
35:3408-3409.
2014
-
Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention..
35:3323-3325.
2014
-
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial..
35:3377-3385.
2014
-
Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry..
35:2864-2872.
2014
-
Ameliorating reperfusion injury in STEMI: dead or alive?.
35:2504-2506.
2014
-
Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial..
35:2516-2523.
2014
-
Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial..
35:2524-2529.
2014
-
An unusual cause of dyspnoea in a young man..
35:1855.
2014
-
Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial..
35:1864-1872.
2014
-
Is there a period of liability with initiation of warfarin in patients with atrial fibrillation?.
35:1834-1835.
2014
-
Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial..
35:1873-1880.
2014
-
Diagnosis of pheochromocytoma on physical examination..
35:1705.
2014
-
Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis..
35:1559-1567.
2014
-
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial..
35:1541-1550.
2014
-
The organization, function, and outcomes of ST-elevation myocardial infarction networks worldwide: current state, unmet needs and future directions..
35:1526-1532.
2014
-
Early management of atrial fibrillation to prevent cardiovascular complications..
35:1448-1456.
2014
-
Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial..
35:1041-1050.
2014
-
The enigmatic search for optimal DAPT duration..
35:951-954.
2014
-
Large simple trials: really, it can't be that simple!.
35:549-551.
2014
-
Large streamlined trials in cardiovascular disease..
35:544-548.
2014
-
The appropriate and justified use of medical radiation in cardiovascular imaging: a position document of the ESC Associations of Cardiovascular Imaging, Percutaneous Cardiovascular Interventions and Electrophysiology..
35:665-672.
2014
-
Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis..
35:455-469.
2014
-
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial..
35:224-232.
2014
-
Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT..
35:106-115.
2014
-
Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke..
35:250-256.
2014
-
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF..
35:242-249.
2014
-
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial..
35:233-241.
2014
-
Natriuretic peptide-guided heart failure management..
35:16-24.
2014
-
Learning from regional heterogeneity in outcomes of patients with acute myocardial infarction..
34:3171-3172.
2013
-
Physical activity in patients with stable coronary heart disease: an international perspective..
34:3286-3293.
2013
-
Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial..
34:3117-3127.
2013
-
Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF..
34:3128-3136.
2013
-
A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial..
34:2481-2489.
2013
-
Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial..
34:2271-2280.
2013
-
Atrial fibrillation: a spectrum of risk with a uniform treatment effect of novel anticoagulants?.
34:2429-2431.
2013
-
Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial..
34:2464-2471.
2013
-
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial..
34:1723-1731.
2013
-
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis..
34:1670-1680.
2013
-
Biomarkers in atrial fibrillation: a clinical review..
34:1475-1480.
2013
-
Phosphate: a novel cardiovascular risk factor..
34:1099-1101.
2013
-
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis..
34:1204-1214.
2013
-
Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint..
34:903-908.
2013
-
Implementation of standardized assessment and reporting of myocardial infarction in contemporary randomized controlled trials: a systematic review..
34:894-902d.
2013
-
Spousal depression, anxiety, and suicide after myocardial infarction..
34:649-656.
2013
-
Influence of baseline left ventricular function on the clinical outcome of surgical ventricular reconstruction in patients with ischaemic cardiomyopathy..
34:39-47.
2013
-
Mechanical dyssynchrony evaluated by tissue Doppler cross-correlation analysis is associated with long-term survival in patients after cardiac resynchronization therapy..
34:48-56.
2013
-
Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial..
33:2821-2830.
2012
-
Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice..
33:2782-2795.
2012
-
Clinical update: Remaining challenges and opportunities for improvement in percutaneous transradial coronary procedures..
33:2521-2526.
2012
-
Road mapping ATLAS ACS 2: are we there yet?.
33:2510-2512.
2012
-
Third universal definition of myocardial infarction..
33:2551-2567.
2012
-
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document..
33:2403-2418.
2012
-
Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study..
33:2151-2162.
2012
-
The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction..
33:2044-2053.
2012
-
Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community..
33:1734-1741.
2012
-
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis..
33:1750-1757.
2012
-
Putting risk prediction in atrial fibrillation into perspective..
33:1431-1433.
2012
-
Adjustment of the GRACE score by growth differentiation factor 15 enables a more accurate appreciation of risk in non-ST-elevation acute coronary syndrome..
33:1095-1104.
2012
-
Toward a therapeutic window for antiplatelet therapy in the elderly..
33:1187-1189.
2012
-
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial..
32:2933-2944.
2011
-
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes..
32:2945-2953.
2011
-
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)..
32:2999-3054.
2011
-
Long-term prognosis associated with J-point elevation in a large middle-aged biracial cohort: the ARIC study..
32:3098-3106.
2011
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial..
32:2781-2789.
2011
-
Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy..
32:2412-2419.
2011
-
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment..
32:2387-2394.
2011
-
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome..
32:2541-2554.
2011
-
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology..
32:1854-1864.
2011
-
Who should have a routine early invasive approach after fibrinolytic therapy?.
32:1961-1963.
2011
-
Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology..
32:1673-1686.
2011
-
Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT..
32:1622-1630.
2011
-
The future of clinical trials in secondary prevention after acute coronary syndromes..
32:1583-1589.
2011
-
Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study..
32:1519-1534.
2011
-
Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients..
32:574-580.
2011
-
Fractal analysis of retinal microvasculature and coronary heart disease mortality..
32:422-429.
2011
-
Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium..
32:205-217.
2011
-
Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis..
31:2156-2169.
2010
-
Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial..
31:1701-1707.
2010
-
Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial..
31:1708-1716.
2010
-
Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals: an international perspective..
31:1328-1336.
2010
-
Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events..
31:1449-1456.
2010
-
Influence of functional deficiency of complement mannose-binding lectin on outcome of patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention..
31:1181-1187.
2010
-
Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis..
31:1257-1265.
2010
-
The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences..
31:1188-1196.
2010
-
Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria..
31:806-814.
2010
-
Towards a new order in cardiovascular medicine: re-engineering through global collaboration..
31:911-917.
2010
-
Clinical trials and registries in cardiovascular disease: competitive or complementary?.
31:520-521.
2010
-
Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The global registry of acute coronary events..
31:667-675.
2010
-
Resolution of ST-segment depression: A new prognostic marker in ST-segment elevation myocardial infarction..
31:573-581.
2010
-
The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative..
31:552-560.
2010
-
Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications..
31:227-235.
2010
-
Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial..
31:211-221.
2010
-
Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes..
31:50-58.
2010
-
Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention..
30:2575-2583.
2009
-
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry..
30:2318-2326.
2009
-
Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial..
30:2226-2232.
2009
-
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis..
30:2213-2219.
2009
-
Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial..
30:2019-2028.
2009
-
Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial..
30:1457-1466.
2009
-
Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)..
30:1450-1456.
2009
-
Amiodarone for the prevention of sudden cardiac death: a meta-analysis of randomized controlled trials..
30:1245-1253.
2009
-
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes..
30:1195-1202.
2009
-
Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery..
30:995-1004.
2009
-
Reperfusion ventricular arrhythmia 'bursts' predict larger infarct size despite TIMI 3 flow restoration with primary angioplasty for anterior ST-elevation myocardial infarction..
30:757-764.
2009
-
Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes..
30:655-661.
2009
-
Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure..
30:338-345.
2009
-
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007..
30:152-161.
2009
-
Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme..
29:3022-3028.
2008
-
Is thrombogenesis related to residual platelet function in ischaemic heart disease?.
29:3065.
2008
-
Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry..
29:3052-3060.
2008
-
Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme..
29:2641-2650.
2008
-
Patterns and prognostic implications of low high-density lipoprotein levels in patients with non-ST-segment elevation acute coronary syndromes..
29:2480-2488.
2008
-
A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF..
29:1983-1991.
2008
-
Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial..
29:1827-1833.
2008
-
Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad..
29:1729-1738.
2008
-
Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme..
29:1377-1385.
2008
-
Is female gender an independent risk factor for early mortality in coronary artery bypass surgery? (Abstract).
19 (Suppl):413-413.
1998
-
Risk stratification in coronary surgery.
19 (Suppl):413-413.
1998
-
The association between vegetation size and surgical treatment on 6-month mortality in left-sided infective endocarditis.
2019
-
Diuretic response in acute heart failure: clinical characteristics and prognostic significance.
2014